Veracyte, Inc. (Nasdaq: VCYT) and Decipher Biosciences, Inc., a commercial-stage precision oncology company focused on urologic cancers, today announced they have entered into a definitive agreement through which Veracyte will acquire Decipher, further solidifying Veracyte’s global leadership in the genomic cancer diagnostics market while accelerating revenue growth.
Read the full article: Veracyte to Acquire Decipher Biosciences //
Source: https://www.businesswire.com/news/home/20210203005354/en/Veracyte-to-Acquire-Decipher-Biosciences